Alkeus Pharmaceuticals

Alkeus Pharmaceuticals is a late-stage biopharmaceutical company dedicated to developing treatments for severe and incurable eye diseases. Alkeus's lead candidate drug, ALK-001, is an oral investigational drug currently being studied in a Phase 2 clinical trial for the treatment of Stargardt disease and a Phase 3 clinical trial for geographic atrophy secondary to dry age-related macular degeneration (AMD).